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Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding 
Researchers)—variants in the spellings of drug names 
in PubMed: a database review
Robin E Ferner,1,2 Jeffrey K Aronson3 
ABSTRACT
ObjeCtive
To examine how misspellings of drug names could 
impede searches for published literature.
Design
Database review.
Data sOurCe
PubMed.
review methODs
The study included 30 drug names that are commonly 
misspelt on prescription charts in hospitals in 
Birmingham, UK (test set), and 30 control names 
randomly chosen from a hospital formulary (control 
set). The following definitions were used: standard 
names—the international non-proprietary names, 
variant names—deviations in spelling from standard 
names that are not themselves standard names in 
English language nomenclature, and hidden reference 
variants—variant spellings that identified publications 
in textword (tw) searches of PubMed or other 
databases, and which were not identified by textword 
searches for the standard names. Variant names were 
generated from standard names by applying letter 
substitutions, omissions, additions, transpositions, 
duplications, deduplications, and combinations of 
these. Searches were carried out in PubMed (30 June 
2016) for “standard name[tw]” and “variant name[tw] 
NOT standard name[tw].”
results
The 30 standard names of drugs in the test set gave 
325 979 hits in total, and 160 hidden reference variants 
gave 3872 hits (1.17%). The standard names of the 
control set gave 470 064 hits, and 79 hidden reference 
variants gave 766 hits (0.16%). Letter substitutions 
(particularly i to y and vice versa) and omissions 
together accounted for 2924 (74%) of the variants. 
Amitriptyline (8530 hits) yielded 18 hidden reference 
variants (179 (2.1%) hits). Names ending in “in,” “ine,” 
or “micin” were commonly misspelt. Failing to search 
for hidden reference variants of “gentamicin,” 
“amitriptyline,” “mirtazapine,” and “trazodone” would 
miss at least 19 systematic reviews. A hidden reference 
variant related to Christmas, “No-el”, was rare; 
variants of “X-miss” were rarer.
COnClusiOn
When performing searches, researchers should 
include misspellings of drug names among their 
search terms.
Introduction
Variant spellings of drug names can cause confusion, 
which could lead to serious harm.1 2 Nevertheless, these 
names are expected to be correctly spelled and indexed 
in published work. We have tested this assumption, 
which underlies many search strategies for systematic 
reviews and meta-analyses of therapeutic interventions.
Methods
We defined the following types of drug names:
•	 Standard name: the international non-proprietary 
name (INN)3 or (if there was no INN) the British 
Approved Name (BAN; box 1).
•	 Variant name: any deviation in spelling from the 
standard name that was not itself a standard name in 
English language nomenclatures, such as BANs or US 
Adopted Names (USANs). For example, we did not 
regard thimerosal (USAN) as a transpositional vari-
ant of thiomersal (INN), although many papers would 
be missed by not searching for both.
•	 Hidden reference variant: a variant spelling that, when 
used as a textword search term in PubMed and other 
databases, identified publications that were not identi-
fied by searching for the standard name as a textword.
Senior pharmacists from hospitals in Birmingham, 
UK provided 30 examples of drug names that were com-
monly misspelt on hospital prescription charts. We 
then chose a control set of 30 drugs at random from the 
Sandwell and West Birmingham Hospitals NHS Trust 
formulary. We ran a search in PubMed4 on 30 June 2016 
for textword instances of the standard name of each 
drug and for spelling variants created by the following 
types of changes:
•	 Substitutions (eg, i to y and vice versa; one unac-
cented vowel to another vowel or y; soft c to s and 
vice versa; hard c to k and vice versa; ch to k; f to ph 
WhAT IS AlReAdy knoWn on ThIS TopIC
Spelling errors are not uncommon in databases such as PubMed and Medline
Drug names are frequently misspelt in these databases and in hospital 
prescription charts
WhAT ThIS STudy AddS
Database searches using only drug names spelt correctly will miss relevant 
references in which the names are spelt incorrectly
These references, which include systematic reviews, will remain hidden unless 
searches are also undertaken using possible misspellings
Authors and editors should be more vigilant about spelling drug names correctly, 
and indexers of databases such as PubMed should cross index incorrect spelling 
variants to correctly spelt names in both directions
When performing searches involving drug names, researchers should include 
incorrect spellings among their search terms
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and vice versa; ide to ine and vice versa; m to n and 
vice versa; th to t; x to ks)
•	 Omissions (eg, prednisolone to pednisolone; pro-
pranolol to popranolol or propanolol; omission of 
final e)
•	 Additions (eg, cotrimoxazole/clotrimazole to clotri-
moxazole; addition of final e)
•	 Transpositions (eg, furosemide to fruosemide; fil-
grastim to filgastrim)
•	 Duplications and deduplications (eg, l to ll and vice 
versa; n to nn and vice versa)
•	 Combination of changes (eg, gentamicin to gentamy-
cine; amitriptyline to amytriptilin).
We searched for “standard name[tw]” (where tw=tex-
tword) and noted the number of hits. We then searched 
for “variant spelling[tw] NOT standard name[tw]” and 
added together the number of hits for each name over 
all its variant spellings. We thus determined the num-
ber of hits that would have been missed by searching 
only for the standard name. We checked whether the 
retrieved references were systematic reviews, including 
meta-analyses.
Results
numbers of hits in Pubmed after use of standard 
names and hidden reference variant spellings
Standard names of the test set of 30 drugs gave 325 979 
hits; 160 hidden reference variants produced 3872 hits 
(1.19%; range 0-2068; median 49). Standard names of 
the control set gave 470 064 hits. Of 208 possible hidden 
reference variants, we found 79, which gave 766 hits 
(0.16%; range 0-115; median 16). Amitriptyline (8530 
hits) had 18 hidden reference variant spellings (179 hits; 
2.06%), the most variant names for a single standard 
name (tables 1 and 2).
types of variant
Table 3 shows frequencies of the different types of spell-
ing variants.
box 1: some national drug naming systems
•	A panel of international nomenclature experts assigns recommended international 
non-proprietary names (rINNs) to drugs, under the aegis of the World Health 
Organization.
•	Occasionally, an objection is raised to a name. If agreement cannot be reached, the 
name remains a proposed INN (pINN). Nearly 5% of all INNs are pINNs. For example, 
amantadine was proposed in 1965, but it has not become a rINN because an 
objection remains on file.
•	The best known national drug naming systems are the British Approved Name 
(BAN), dénomination commune française (DCF), Japanese Accepted Name for 
pharmaceuticals (JAN), and US Adopted Name (USAN).
•	The UK uses the INN as the BAN, except for adrenaline and noradrenaline (INNs 
epinephrine and norepinephrine). That is not the case elsewhere. For example, 
compare paracetamol (INN) and acetaminophen (USAN); salbutamol (INN) and 
albuterol (USAN); rifampicin (INN) and rifampin (USAN); glibenclamide (INN), and 
glyburide (USAN).
•	Some compounds that do not have INNs can still have a BAN, using a chemical 
name—for example, acetylsalicylic acid and glyceryl trinitrate.
•	Mixtures of drugs do not have INNs. In some cases, BANs have been specially 
created for such mixtures (eg, co-codamol is the BAN for a mixture of codeine and 
paracetamol).
table 3 | Frequencies of 239 different types of hidden 
reference variants of 60 drug names (test and control 
sets combined). we found no variants of aprepitant
single changes (n=207) and 
combinations (n=31) Frequencies (no (%))
Substitutions (total) 108 (45)
 Single 91
 Double 16
 Treble 1*
Omissions 67 (28)
Additions 20 (8)
Transpositions 11 (5)
Duplications 2 (1)
Deduplications 0
Any combination of these aberrations 31 (13)
*Amytryptiline (two hits).
table 1 | hidden reference variants and number of 
Pubmed hits of the standard name amitriptyline
variant name no of hits
Amitiptyline 1
Amitriptilin 8
Amitriptiline 8
Amitriptyine 1
Amitriptylin 14
Amitriptyllin 1
Amitriptylline 2
Amitryptilin 4
Amitryptiline 80
Amitryptilline 1
Amitryptylin 1
Amitryptyline 32
Amitryptylline 1
Amytriptilin 2
Amytriptiline 10
Amytriptylin 1
Amytriptyline 10
Amytryptiline 2
table 2 | numbers of Pubmed hits of hidden reference 
variant spellings* of the standard name amitriptyline 
variant spellings  
(i to y substitutions 
(and vice versa))
no of hits
spelling with 
single l
spelling with 
double ll
without 
final e
Plus 
final e
without 
final e
Plus 
final e
i–i–i 8 8 0 0
i–i–y 14 † 1 2
i–y–i 4 80 0 1
i–y–y 1 32 0 1
y–i–i 2 10 0 0
y–i–y 1 10 0 0
y–y–i 0 2 0 0
y–y–y 0 0 0 0
Total 30 142 1 4
*Included one case of the variant “amitiptyline” lacking the r, and one of 
“amitriptyine” lacking the l. There was no variant in which the final i was 
replaced by a y.
†Amitriptyline, the standard name, gave 8530 hits.
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We examined names ending in “micin” in detail. 
Most of the errors occurred with the standard form 
“gentamicin” compared with the variant “gentamycin,” 
which resulted in 21 384 and 1977 hits (9.25%), respec-
tively. The ending “mycin” was also often substituted in 
fidoxamicin (2.02%) and netilmicin (2.46%; table 4 ). In 
contrast, in 19 standard drug names ending in “mycin” 
(218 415 hits), the hidden reference variant “micin” was 
rare (157 hits (0.07%); table 5).
Names ending in “in” or “ine” were also likely to gen-
erate hidden spelling variants by addition or omission 
of the final “e.” The 28 standard names of this type in 
the test and control sets combined yielded 296 973 hits 
and hidden spelling variants yielded 3450 hits (1.16%), 
compared with 499 070 hits and 1188 hits (0.24%), 
respectively, for the other 32 names.
searches for systematic reviews
We found 87 systematic reviews or meta-analyses that 
mentioned the standard name gentamicin, 0.41% of all 
hits for “gentamicin[tw].” We found six further system-
atic reviews (6.5% of the total) in PubMed after search-
ing for hidden reference variants of gentamicin. In 
Medline, the equivalent search for “gentamicin.af.” 
(where af=all fields) identified 141 systematic reviews, 
with 19 782 hits (0.71%). The hidden reference variants, 
with 863 hits, identified 15 additional systematic 
reviews (9.6% of the total).
Similarly, for amitriptyline, we found 179 systematic 
reviews in PubMed and another five as hidden reference 
variants. Corresponding numbers were 110 and six for 
mirtazapine and 47 and two for trazodone. Thus, for 
these drugs, 19 systematic reviews of 455 (4.2%) would 
have been missed by searching for the standard spell-
ings only.
a variant index score
We scored various features of standard names as fol-
lows:
•	 Number of letters
•	 Number of syllables
•	 Number of unaccented vowels + 1
•	 Number of incidences of i and y + 1
•	 Number of incidences of f or ph + 1
•	 Number of potential duplications or deduplications 
(l, m, n, s, t) + 1
•	 Standard names ending in “in” or “ine” (no=1, yes=2)
•	 Standard names ending in “micin” (no=1, yes=2).
The product of these factors, a variant index score, 
was on average much higher in the test group (range 
54-4480; median 524) than the control group (range 
36-1440; median 272).
discussion
We have uncovered a potential indirect harm from 
incorrect variant spellings of drug names that has not 
previously been investigated, to our knowledge, 
although others have reported misspelt general medical 
textwords in Medline8  and misspellings of the word 
“random” and its derivatives in Medline and EMBASE.9 
Difficulties in recognising and distinguishing drug 
names can lead to clinical harm directly, for example, 
when one drug name is read as another. Here, we 
demonstrate the extent to which medical literature 
searches can be frustrated by textword searches that 
fail to include variant spellings, since articles refer-
enced only by the variant spelling will remain hidden. 
PubMed offers the correct spelling (eg, gentamicin) 
when you enter an incorrect one (eg, gentamycin), but 
not the other way round—searching for “gentamicin[tw]” 
does not yield incorrect spellings.
Information in systematic reviews can be lost if the 
review is indexed under a hidden reference variant and 
not under the textword for the standard name. The 
problem is not limited to PubMed. In Medline, 13 sys-
tematic reviews were hidden under the variant spelling 
“gentamycin.” In the Cochrane Database of Systematic 
Reviews,5 there were 15 systematic reviews of “gentami-
cin,” but use of the term “gentamycin” identified four 
otherwise hidden reviews.
The most obvious way to mitigate this problem is for 
authors and editors to take care over the correct spell-
ings of drug names. Indexing could be improved, espe-
cially by ensuring that standard names are always used 
table 4 | number of Pubmed hits for drugs with standard names ending in “micin” 
compared with hidden reference variants ending in “mycin”
standard name 
(“micin”) no of hits variant (“mycin”) no of hits ratio (%)*
Fidaxomicin 248 Fidaxomycin 5 2.02 
Gentamicin 21 384 Gentamycin 1977 9.25
Netilmicin 1875 Netilmycin 46 2.46
Ozogamicin 539 Ozogamycin 13 2.41
Total 24 046 — 2041 8.49
*Number of hits of variant divided by number of hits of standard name.
table 5 | number of Pubmed hits for drugs with standard names ending in “mycin” 
compared with hidden reference variants ending in “micin”
standard name 
(“mycin”) no of hits variant (“micin”) no of hits ratio (%)*
Azithromycin 6797 Azithromicin 4 0.06
Bleomycin 17 575 Bleomicin 8 0.05
Capreomycin 570 Capreomicin 1 0.18
Clarithromycin 8827 Clarithromicin 2 0.02
Clindamycin 10 308 Clindamicin 17 0.16
[D]actinomycin 33 800 [D]actinomicin 11 0.03
Daptomycin 2394 Daptomicin 1 0.04
Erythromycin 23 605 Erythromicin 13 0.06
Fosfomycin 2501 Fosfomicin 3 0.12
Kanamycin 12 966 Kanamicin 17 0.13
Lincomycin 3114 Lincomicin 2 0.06
Mitomycin 18 503 Mitomicin 15 0.08
Neomycin 12 678 Neomicin 4 0.03
Spectinomycin 2467 Spectinomicin 1 0.04
Spiramycin 1409 Spiramicin 1 0.07
Streptomycin 29 265 Streptomicin 4 0.01
Telithromycin 909 Telithromicin 0 0
Tobramycin 6822 Tobramicin 30 0.44
Vancomycin 23 905 Vancomicin 23 0.10
Total 218 415 — 157 0.07
*Number of hits of variant divided by number of hits of standard name. 
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table 6 | “no-el” and “X-miss” hidden reference variants of some drug names, mostly not included in the main study
standard name no of Pubmed hits hidden reference variant
no of Pubmed 
hits
no-el variants
Acetylcholine 87 367 Acetycholine/acetylchoine 59
Acetylcysteine 15 552 Acetycysteine 1
Aclidinium 143 Acidinium 2
Adrenaline 18 258 Adrenaine 1
Aflibercept 885 Afibercept 1
Agalsidase 389 Agasidase 1
Albendazole 5206 Abendazole 2
Alglucosidase 76 Aglucosidase 1
Allopurinol 9168 Alopurinol 7
Alprazolam 2408 Aprazolam 3
Alteplase 1434 Ateplase 1
Amisulpride 898 Amisupride 2
Amitriptyline 8530 Amitriptyine 1
Carmellose 50 Carmelose 2
Chlorambucil 4744 Chorambucil 1
Chloramphenicol 38 566 Choramphenicol 18
Chlorhexidine 9737 Chorhexidine 1
Chloroquine 19 061 Choroquine 5
Ending in “cillin” (15 names) 152 776 Ending in “cilin” (15 names) 148
Clotrimazole 2637 Cotrimazole 5
Colchicine 18 500 Cochicine 9
Cyclophosphamide 62 552 Cycophosphamide 2
Desflurane/sevoflurane 9533 Desfurane/sevofurane 3
Diclofenac 10 526 Dicofenac 3
Diethylstilbestrol 10 000 Diethystilbestrol/diethylstibestrol 26
Doxycycline* 13 592 Doxycycine 1
Enzalutamide 615 Enzautamide 1
Ethinylestradiol 2424 Ethinyestradiol 2
Filgrastim 2220 Figrastim 1
Ending in “floxacin” (5 names) 42 376 Ending in “foxacin” (5 names) 13
Ending in “flozin” (3 names) 981 Ending in “fozin” (3 names) 4
Fluorouracil 46 951 Fuorouracil 4
Flurbiprofen 2376 Furbiprofen 1
Flutamide 3344 Futamide 1
Follitropin and urofollitropin 668 Folitropin and urofolitropin 11
Glibenclamide 7421 Glibencamide 5
Gliclazide 1138 Glicazide 7
Hydrochlorothiazide 8093 Hydrochorothiazide 2
Hydroxyethylcellulose* 561 Hydroxyethylcelluose/ hydroxyethycellulose 3
Immunoglobulin 283 887 Immunogobulin 4
Infliximab 11 000 Infiximab 5
Insulin 351 197 Insuin 1
Leflunomide 2002 Lefunomide 3
Melphalan 9699 Mephalan 7
Methyldopa 4560 Methydopa 1
Methylphenidate 7830 Methyphenidate 3
Naltrexone 8669 Natrexone 1
Olmesartan 1321 Omesartan 1
Oxaliplatin 8056 Oxalipatin 1
Penicillamine 10 852 Penicilamine 14
Paclitaxel 28 899 Pacitaxel 4
Phenylephrine 20 623 Phenyephrine 4
Ending in “phylline” (3 names) 5306 Ending in “phyline” (3 names) 12
Propylthiouracil 5103 Propythiouracil 2
Prostaglandin(s) 115 753 Prostagandin(s) 4
Repaglinide 676 Repaginide 1
Rosiglitazone 5570 Rosigitazone 1
Sildenafil 6348 Sidenafil 3
Sulfadoxine 2693 Sufadoxine 1
Sulfamethoxazole 15 466 Sufamethoxazole 3
(Continued)
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when it is possible to identify them. However, even with 
scrupulous indexing, orthographic variants will pose 
challenges, because one cannot expect indexers to seek 
out all variant spellings in a paper for inclusion under a 
MeSH term heading. Researchers could also search for 
all likely variants as textwords, although this would 
pose challenges for names with many potential vari-
ants. For example, 18 variants of amitriptyline returned 
179 hits that would have been hidden using only the 
standard name.
Another solution is to use wild cards, if available. 
Medline allows users to search for words that are spelt 
with alternative letters. For example, a search for “ami-
triptyline.af.” yields 8092 hits. Searching for 
“am#tr#pt#line.af.” uncovers all variant spellings with 
i to y substitutions (and vice versa) in amitriptyline 
(table 2), revealing 123 hidden reference variants. The 
textword “am#tr#pt#l*.af.” truncated at the letter l 
uncovers variants of the last few letters (for example, 
ending in “lin,” “line,” “llin,” “lline”) without sacrific-
ing specificity, and gives further hits. However, this 
does not exhaust all variant forms. For example, the 
hidden reference variant amitiptyline, generated by 
omission, was missed.
The variant index score that we have calculated from 
eight important features associated with hidden refer-
ence variants affords insight into the likelihood that 
newly coined names might prove problematic. Combin-
ing the index score with Trigram-2b or the Levenshtein 
distance, which measure how likely names are to be con-
fused,6 7 could help reduce problems with new names.
It has been suggested that all relevant spelling vari-
ants should be included in search strategies. However, 
this recommendation did not refer to incorrectly spelt 
variants as opposed to variants in standard spelling, 
such as those between US and UK English (eg, anemia 
and anaemia), and did not mention drug names.10
limitations
Although we systematically generated variants of stan-
dard names of drugs (as described in the methods), we 
could have missed some variants, and underestimated 
the frequencies of hidden reference variants. In the Xmas 
spirit, we offer table 6, illustrating other variant spellings.
Note added in proof: Both authors found it hard to proofread an 
article intended to contain many variant spellings. We apologise if, 
inadvertently, we have sometimes spelt drug names correctly.
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table 6 | “no-el” and “X-miss” hidden reference variants of some drug names, mostly not included in the main study
standard name no of Pubmed hits hidden reference variant
no of Pubmed 
hits
Sulphonamide 8063 Sufonamide 1
Valproic 13 432 Vaproic 1
Zolmitriptan 565 Zomitriptan 3
Total 1 549 326 442 (0.028)
X-miss variants
Amoxicillin 16 411 Amoicillin 1
Doxycycline* 13 592 Doycycline 1
Hydroxyethylcellulose* 561 Hydroyethylcellulose 1
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Total 540 832 5 (0.0009%)
*Do[x]cyc[l]ine and hydro[x]yethy[l]cellu[l]ose each feature twice.
